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demographics. RESULTS: What single intervention should we
currently use? HPV vaccine (three doses, costing $120 per dose at
age 12) is not cost-effective as its cost per Quality-Adjusted-Life-
Year (QALY) is more than three times the magnitude of the GNP
per head. Adoption of a thrice a lifetime PAP screening strategy
dominates (ie: costs less and adds more QALYs) the current
strategy, which opportunistically gives PAP screens to 12.2% of
females annually. However, because of the inevitable future fall in
the HPV vaccine price, it is not recommended to abandon the
current opportunistic PAP smear strategy for a more systematic
thrice a lifetime strategy. When should the HPV vaccination be
adopted? Assuming non-waning efﬁcacy, HPV vaccinations
become cost effective when cost falls below $97 per dose, become
very cost-effective (ie: cost per QALY < per capita GNP) when
cost falls below $50 per dose and become cost-saving (ie: gains in
decreased treatment costs exceed increased screening, program
and training costs) when cost per dose falls below the $27.20
threshold. After HPV vaccination is adopted, should we still have
screening programs? Expansion of the PAP program to a penta-
annual PAP program would provide the most additional QALYs
within cost-effectiveness constraints. CONCLUSION: PAP com-
pliancy should be increased to 20.0% per annum, both before
and after the vaccination is introduced. An HPV vaccination
program should be adopted when the vaccine price drops to a
level that it becomes affordable to the Ministry of Health or falls
below $20.44 per dose, providing a cost-saving incentive to the
health insurance funds.
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OBJECTIVE: Geﬁtinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, is a new treatment option for
non-small cell lung cancer (NSCLC). Some studies have found
better clinical outcomes for geﬁtinib treatment in women, never-
smokers, certain mutation in the tumor EGFR gene, and patients
with adenocarcinoma and in East Asian ethnicity. However,
geﬁtinib is currently regarded as a salvage treatment rather than
a ﬁrst-line option. The objective of this study was to assess the
cost-effectiveness of geﬁtinib for ﬁrst-line treatment of the inop-
erable, chemo-naïve NSCLC patients in Taiwan. METHODS:
We developed a Markov model of the cost, quality of life, sur-
vival, and incremental cost-effectiveness of the alternative option
with geﬁtinib for ﬁrst-line treatment, as compared with current
practice of platinum-based chemotherapy regiments. Variables of
clinical effectiveness were determined from corresponding trials.
The economic analysis adopted the health care payer’s perspec-
tive, and only direct medical costs were taken into account.
RESULTS: Use of geﬁtinib for ﬁrst-line treatment had a better
mean survival than platinum-based chemotherapies (13.1 versus
11.6 months) while increasing lifetime cost. Given the base-case
assumptions, we found that geﬁtinib increased life expectancy by
1.49 months, or 0.80 quality-adjusted months, at an estimated
cost of $4,140 per treated patient, for an incremental cost-
effectiveness ratio (ICER) of $62,100 per quality-adjusted life-
year (QALY). The ICER would decrease to $48,600 per QALY
gained when such analysis was applied to a subgroup of patients
with molecular marker of EGFR exon 19 deletion or L858R
mutations while they had a signiﬁcantly longer mean survival of
20.8 months. Sensitivity analyses showed that this ICER
remained below $100,000 per QALY for all model variables.
CONCLUSION: Use of geﬁtinib for ﬁrst-line treatment has a
cost-effectiveness ratio below $50,000 per QALY gained in
advanced NSCLC patients with preferred clinical characteristics
in which a signiﬁcant extension of overall survival has been
demonstrated.
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OBJECTIVE: Currently imatinib resistant or intolerant CML
patients have minimally effective therapies available. Dasatinib
binds to the protein Bcr-Abl; it binds also to active and inactive
forms of protein, while imatinib binds only to the inactive forms.
Therefore, mutations that affect the active form can lead to
resistance to imatinib. A Markov model was built to evaluate the
long-term cost-effectiveness of dasatinib in the treatment of adult
CML patients, after resistance or intolerance to imatinib.
METHODS: The model consists of an initial within-trial period
in which best response rates observed from the clinical trials
are used. Response was deﬁned as best response of complete
hematologic response (CHR), minor cytogenetic response (CyR),
minimal CyR, partial CyR, and complete CyR. The model simu-
lates patients moving between health states using progression
probabilities derived from the literature and BMS clinical trials.
The time horizon was the lifetime of patients in the cohort,
allowing evaluation of life expectancy and lifetime costs. Brazil-
ian costs and health resource estimates were applied to the treat-
ment of the different phases of CML. RESULTS: For CML
patients in CP dasatinib provided 0.66 QALYs per patient and
the ICER was R$80,000 with an additional life expectancy of
0.98 years. In the case of AP dasatinib provided an additional life
expectancy of 3.48 years with a ICER of R$91,000. And in the
BP dasatinib provided an additional life expectancy of 1.91 years
with a ICER of R$123,000. CONCLUSION: The CE analysis
showed that dasatinib is more cost-effective in the resistant or
intolerant patients than imatinib in the three phases of CML with
increased life expectancy with quality. Though there is an incre-
mental cost associated to the treatment with dasatinib, the cost is
related to longer life expectancy and therefore expenditure of
more resources.
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OBJECTIVE: Gastric cancer is the ﬁfth most prevalent cancer
and the ﬁfth cause of cancer-related mortality in Taiwan. The
objective of this study was to access the cost-effectiveness of
capecitabine plus cisplatin (XP) vs. intravenous 5-ﬂuorouracil
plus cisplatin (FP) for the treatment of advanced and metastatic
gastric cancer (AGC) in Taiwan, from a payer’s (Bureau of
National Health Insurance [BNHI]) perspective. METHODS: A
cost-minimization analysis (CMA) was conducted by applying
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